These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. A second coreceptor for HIV in early stages of infection. Balter M Science; 1996 Jun; 272(5269):1740. PubMed ID: 8650568 [No Abstract] [Full Text] [Related]
45. [[ABC of the antivirals] Project Inform]. Sidahora; 1996; ():19-32. PubMed ID: 11364292 [TBL] [Abstract][Full Text] [Related]
46. Association of the CCR5delta32 mutation with improved response to antiretroviral therapy. Valdez H; Purvis SF; Lederman MM; Fillingame M; Zimmerman PA JAMA; 1999 Aug; 282(8):734. PubMed ID: 10463706 [No Abstract] [Full Text] [Related]
47. New drugs for HIV therapy. Rockstroh JK J HIV Ther; 2005 Dec; 10(4):66-7. PubMed ID: 16519244 [No Abstract] [Full Text] [Related]
48. CCR5 antagonists: a new tool in fighting HIV. Jülg B; Goebel FD J HIV Ther; 2005 Dec; 10(4):68-71. PubMed ID: 16519245 [TBL] [Abstract][Full Text] [Related]
49. Salvage therapy for patients failing their current antiretroviral regimen. Albrecht MA AIDS Clin Rev; 2000-2001; ():139-91. PubMed ID: 10999220 [No Abstract] [Full Text] [Related]
50. Vaccination and HIV-1 replication during highly active antiretroviral therapy. Kroon FP; Beersma MF; Kroes AC; Groeneveld PH; van Dissel JT AIDS; 1999 Jan; 13(1):135-6. PubMed ID: 10207556 [No Abstract] [Full Text] [Related]
51. HIV experts vs. sequencers in patent race. Marshall E Science; 1997 Feb; 275(5304):1263. PubMed ID: 9064781 [No Abstract] [Full Text] [Related]
52. Tribulations and trials in HIV disease, Part 2. Boyle BA AIDS Read; 2006 Jun; 16(6):291-4. PubMed ID: 16795918 [No Abstract] [Full Text] [Related]
53. Long-term suppression of HIV replication in patients with sustained benefit on zidovudine monotherapy. Gómez-Cano M; Soriano V; Pérez-Olmeda M; Machuca A; Rodríguez-Rosado R; Valencia E; Moreno V; Gutiérrez M; González-Lahoz J AIDS; 1998 May; 12(8):964-6. PubMed ID: 9631158 [No Abstract] [Full Text] [Related]
55. The emerging race to cure HIV infections. Cohen J Science; 2011 May; 332(6031):784-5, 787-9. PubMed ID: 21566173 [No Abstract] [Full Text] [Related]
56. Update of the drug resistance mutations in HIV-1: 2004. Johnson VA; Brun-Vézinet F; Clotet B; Conway B; D'Aquila RT; Demeter LM; Kuritzkes DR; Pillay D; Schapiro JM; Telenti A; Richman DD Top HIV Med; 2004; 12(4):119-24. PubMed ID: 15516709 [No Abstract] [Full Text] [Related]
57. High turnover of HIV in blood revealed by new studies. Cohen J Science; 1995 Jan; 267(5195):179. PubMed ID: 7809623 [No Abstract] [Full Text] [Related]
58. Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitor. Grant P; Taylor J; Cain P; Short W; Gallant J; Farthing C; Thal G; Coakley E; Zolopa A Clin Infect Dis; 2009 Mar; 48(5):680-2. PubMed ID: 19191657 [TBL] [Abstract][Full Text] [Related]
59. Periodic multidrug therapy in a within-host virus model. Browne CJ; Pilyugin SS Bull Math Biol; 2012 Mar; 74(3):562-89. PubMed ID: 21822766 [TBL] [Abstract][Full Text] [Related]
60. Antiretroviral therapy in human immunodeficiency virus-infected individuals. Spooner KM Adv Intern Med; 1998; 43():373-402. PubMed ID: 9506188 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]